212 related articles for article (PubMed ID: 29330579)
1. [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].
Troyanova-Slavkova S; Eickenscheidt L; Dumann K; Kowalzick L
Hautarzt; 2018 Aug; 69(8):674-680. PubMed ID: 29330579
[TBL] [Abstract][Full Text] [Related]
2. Severe de-novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma.
Di Altobrando A; Bruni F; Alessandrini A; Starace M; Misciali C; Piraccini BM
Dermatol Ther; 2020 May; 33(3):e13363. PubMed ID: 32239596
[TBL] [Abstract][Full Text] [Related]
3. Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
Thomas M; Armenti ST; Ayres MB; Demirci H
JAMA Ophthalmol; 2018 May; 136(5):553-556. PubMed ID: 29677240
[TBL] [Abstract][Full Text] [Related]
4. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer.
C Guven D; Kilickap S; Guner G; Taban H; Dizdar O
J Oncol Pharm Pract; 2020 Jan; 26(1):256-258. PubMed ID: 31566114
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab-induced aplastic anemia: A case report and literature review.
Comito RR; Badu LA; Forcello N
J Oncol Pharm Pract; 2019 Jan; 25(1):221-225. PubMed ID: 28825374
[TBL] [Abstract][Full Text] [Related]
6. A Case of De Novo Psoriasis Secondary to Nivolumab in a Patient With Metastatic Renal Cell Carcinoma.
Mullangi S; Ponnam S; Lekkala MR; Koya S
Cureus; 2021 Jun; 13(6):e15703. PubMed ID: 34290912
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab.
Keung YK; Hu EH
J Oncol Pharm Pract; 2019 Jul; 25(5):1261-1264. PubMed ID: 29984627
[TBL] [Abstract][Full Text] [Related]
8. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
Min Lee CK; Li S; Tran DC; Zhu GA; Kim J; Kwong BY; Chang ALS
J Am Acad Dermatol; 2018 Dec; 79(6):1047-1052. PubMed ID: 29857011
[TBL] [Abstract][Full Text] [Related]
9. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy.
Johnson ED; Kerrigan K; Butler K; Patel SB
J Oncol Pharm Pract; 2020 Jan; 26(1):224-227. PubMed ID: 30880569
[TBL] [Abstract][Full Text] [Related]
11. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.
Cooper DS; Meriggioli MN; Bonomi PD; Malik R
J Neuromuscul Dis; 2017; 4(2):169-173. PubMed ID: 28505981
[TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor.
Mathew Thomas V; Bindal P; Ann Alexander S; McDonald K
J Oncol Pharm Pract; 2020 Mar; 26(2):459-461. PubMed ID: 30909794
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
15. The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature.
Tabei A; Watanabe M; Ikeuchi H; Nakasatomi M; Sakairi T; Kaneko Y; Maeshima A; Kaira K; Hirato J; Nojima Y; Hiromura K
Intern Med; 2018 Nov; 57(21):3135-3139. PubMed ID: 29877267
[TBL] [Abstract][Full Text] [Related]
16. New onset of psoriasis during nivolumab treatment for lung cancer.
Chujo S; Asahina A; Itoh Y; Kobayashi K; Sueki H; Ishiji T; Umezawa Y; Nakagawa H
J Dermatol; 2018 Mar; 45(3):e55-e56. PubMed ID: 29205470
[No Abstract] [Full Text] [Related]
17. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
19. Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait.
Saleh K; Bellanger C; Garcia G; Classe M; Even C
Eur J Cancer; 2021 Mar; 145():155-157. PubMed ID: 33476895
[No Abstract] [Full Text] [Related]
20. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
Hida T
Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
